A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 μg ethinylestradiol in the treatment of acne vulgaris: Lesion counts, investigator ratings and subject self-assessment

Journal of Drugs in Dermatology

Volumn 8, Issue 9, 2009, Pages 837-844

  Maloney, J Michael ^a   Dietze Jr , Peter ^b   Watson, David ^c   Niknian, Minoo ^d   Lee Rugh, Sooji ^e   Sampson Landers, Carole ^d   Korner, Paul ^f  

^a Cherry Creek Dermatology   (United States)

^b Women's Health Care Inc   (United States)

^c Clinical Trial Center of Colorado   (United States)

^d Bayer HealthCare   (United States)

^e Millennium CRC LLC   (United States)

^f Women's Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; PLACEBO; ANDROSTANE DERIVATIVE; DROSPIRENONE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; COMEDO; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METRORRHAGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PAPULE; PATIENT COMPLIANCE; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349306416     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Krowchuk DP, Lucky AW. Managing adolescent acne. Adolesc Med. 2001;12(2):355-374.
2. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. Fertil Steril. 2001;76:461-468.
3. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000;9:179-187.
4. Gollnick H. Current concepts of the pathogenesis of acne: Implications for drug treatment. Drugs. 2003;63(15):1579-1596. (Pubitemid 36976140)
5. Murphy A, Cropp CS, Smith BS, et al. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril. 1990;53(1):35-39. (Pubitemid 20041312)
6. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990;41(4):345-352. (Pubitemid 20134343)
7. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71(6):409-416. (Pubitemid 40725775)
8. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251. (Pubitemid 26398621)
9. Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761:311-335.
10. Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123-130. (Pubitemid 39207746)
11. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191-198. (Pubitemid 39119980)
12. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492-501. (Pubitemid 41208780)
13. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414-421. (Pubitemid 41676830)
14. Maloney JM, Dietze P, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008;112(4):773-781.
15. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89(4):615-622. (Pubitemid 27133540)
16. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37(5 Pt 1):746-754. (Pubitemid 27500319)
17. Agency for Health Research and Quality. Management of Acne. Summary Evidence Report/Technology Assessment: Number 17. AHRQ Publication No. 01-E018, March 2001. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/clinic/epcsums/acnesum.htm. Accessed November 4, 2008.
18. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140:672-676. (Pubitemid 29191387)
19. Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: Reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol. 1998;78:451-456. (Pubitemid 28505962)
20. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846-850. (Pubitemid 28520293)
21. Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose oral contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol. 2002;47:399-409.
22. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 μg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception. 2008;77(4):249-256.
23. Lucky AW, Koltun W, Thiboutot D, et al. A combined oral contraceptive containing 3-mg drospirenone/20-μg ethinyl estradiol in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008;82:143-150.